How much revenue does RVL Pharmaceuticals make?

RVL Pharmaceuticals reported $49.72 million in revenue for fiscal year 2022, up 184.1% from $17.50 million in fiscal year 2021. In Q2 2023 revenue was $8.26 million.

What companies are similar to RVL Pharmaceuticals?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include RavenQuest BioMed Inc. (RVVQF), HEALTHeUNIVERSE, Inc. (HLUN), PhaseRx, Inc. (PZRXQ), Omnimmune Holdings, Inc. (OMMH).

RVL Pharmaceuticals plc (RVLPQ) Stock

About RVL Pharmaceuticals plc

RVL Pharmaceuticals plc operates as a specialty pharmaceutical company in the United States, Argentina, and Hungary. It focuses on the development and commercialization of pharmaceutical products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas. It is commercializing Upneeq (RVL-1201), an oxymetazoline hydrochloride ophthalmic solution...

At a glance

RVL Pharmaceuticals reported revenue of $49.72 million for fiscal year 2022, up 184.1% from fiscal year 2021, and net income of -$51.69 million. In Q2 2023 (the quarter ended June 30, 2023) revenue was $8.26 million, down 2.2% from a year before.

Figures from company filings; latest fiscal year ended December 31, 2022.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.